BIA
CGTX icon

Barry Investment Advisors’s Cognition Therapeutics CGTX Stock Holding History

Barry Investment Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Hold
10,000
– – ﹤0.01% 102
2026
Q1 		$7.59K Hold
10,000
– – ﹤0.01% 99
2025
Q4 		$13.5K Hold
10,000
– – ﹤0.01% 101
2025
Q3 		$13.5K Buy
+10,000
New +$13.6K ﹤0.01% 107

Other funds holding CGTX

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Barry Investment Advisors's CGTX Position: Q2 2026 in Review

Barry Investment Advisors held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 10,000 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #102.

Barry Investment Advisors first reported a position in CGTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $13.5K in Q4 2025. 7 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Barry Investment Advisors held 10,000 shares of Cognition Therapeutics worth $11.5K as of Q2 2026.
  • Barry Investment Advisors left its Cognition Therapeutics share count unchanged in Q2 2026.
  • Cognition Therapeutics made up ﹤0.01% of Barry Investment Advisors's portfolio in Q2 2026, its #102 holding.
  • Barry Investment Advisors first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Barry Investment Advisors's Cognition Therapeutics position peaked at $13.5K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Barry Investment Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.